{"id":18579,"date":"2014-04-03T09:48:20","date_gmt":"2014-04-03T13:48:20","guid":{"rendered":"https:\/\/cablemanpro.com\/wallstreetpr\/?p=18579"},"modified":"2014-04-03T09:48:20","modified_gmt":"2014-04-03T13:48:20","slug":"mannkind-corporation-nasdaqmnkd-receives-favorable-votes-from-advisory-panel-of-the-fda-for-its-diabetes-treatment","status":"publish","type":"post","link":"https:\/\/cablemanpro.com\/wallstreetpr\/mannkind-corporation-nasdaqmnkd-receives-favorable-votes-from-advisory-panel-of-the-fda-for-its-diabetes-treatment-18579","title":{"rendered":"Mannkind Corporation (NASDAQ:MNKD) Receives Favorable Votes From Advisory Panel Of The FDA For Its Diabetes Treatment"},"content":{"rendered":"<p style=\"text-align: justify;\">Boston, MA 04\/03\/2014 (wallstreetpr) &#8211;\u00a0<b>MannKind Corporation (NASDAQ:MNKD)<\/b> moves a step ahead in getting its first product marketed as the drugmaker\u2019s inhaled diabetes treatment wins the support of a U.S. advisory panel.<\/p>\n<p style=\"text-align: justify;\">Members of an advisory board of the U.S. Food and Drug Administration voted 13-1 for MannKind\u2019s treatment for Type 1 diabetes and 14-0 for its treatment for Type 2 diabetes yesterday. The drug called Afrezza was consented to receive the approval of the FDA by the advisory panel, although the FDA is not bound to accept the suggestion. FDA\u2019s staff expressed disagreement with the suggestion, raising concerns in a March 28 report suggesting that the drug adversely affects the functioning of lungs. The report also claimed that data from a trail obtained by treating Type 1 diabetes patients with the drug was missing.<\/p>\n<p style=\"text-align: justify;\"><b>Selling Partners<\/b><\/p>\n<p style=\"text-align: justify;\">It is being speculated that even if the drug gets the approval, its success in the market would still be a question on account that the Valencia, California based drugmaker will have to approach a partner which could drive sales for the drug. Mannkind Corporation (NASDAQ:MNKD) is already in talks with some companies, as its Chief financial Officer, Matthew Pfeffer said. He said that announcement of a potential partner could be expected soon after FDA gives out its decision, which is due on April 15.<\/p>\n<p style=\"text-align: justify;\"><b>Revenue<\/b><\/p>\n<p style=\"text-align: justify;\">The company has been seeking approval to market the drug for around 8 years, when it had initiated the late stage trails for the drug. According to analysis by the Centers for Disease Control and Prevention, Type 1 diabetes was found in 8.3% of Americans in 2010, while Type 2 is more common among diabetes patients. According to data compiled by analysts at Bloomberg, if approved, Afrezza could generate as much as $534 million in 2018.<\/p>\n<p style=\"text-align: justify;\">Shares of Mannkind Corporation (NASDAQ:MNKD) surged 74% after the news and reached up to $6.99 at the close in New York. This is the highest one day jump of the company\u2019s shares since 2004.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Boston, MA 04\/03\/2014 (wallstreetpr) &#8211;\u00a0MannKind Corporation (NASDAQ:MNKD) moves a step ahead in getting its first product marketed as the drugmaker\u2019s inhaled diabetes treatment wins the [&hellip;]<\/p>\n","protected":false},"author":32,"featured_media":18492,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":{"twitter_2902945987_2902945987":""},"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[264],"tags":[2246,2247],"stock_ticker":[],"class_list":["post-18579","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-health","tag-mannkind-corporation-nasdaqmnkd","tag-nasdaqmnkd","entry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Mannkind Corporation (NASDAQ:MNKD) Receives Favorable Votes From Advisory Panel Of The FDA For Its Diabetes Treatment - Wall Street PR<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/cablemanpro.com\/wallstreetpr\/mannkind-corporation-nasdaqmnkd-receives-favorable-votes-from-advisory-panel-of-the-fda-for-its-diabetes-treatment-18579\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Mannkind Corporation (NASDAQ:MNKD) Receives Favorable Votes From Advisory Panel Of The FDA For Its Diabetes Treatment - Wall Street PR\" \/>\n<meta property=\"og:description\" content=\"Boston, MA 04\/03\/2014 (wallstreetpr) &#8211;\u00a0MannKind Corporation (NASDAQ:MNKD) moves a step ahead in getting its first product marketed as the drugmaker\u2019s inhaled diabetes treatment wins the [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/mannkind-corporation-nasdaqmnkd-receives-favorable-votes-from-advisory-panel-of-the-fda-for-its-diabetes-treatment-18579\" \/>\n<meta property=\"og:site_name\" content=\"Wall Street PR\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/WallStreetPR\/\" \/>\n<meta property=\"article:published_time\" content=\"2014-04-03T13:48:20+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/04\/MannKind-Corp..jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"441\" \/>\n\t<meta property=\"og:image:height\" content=\"114\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Greg Folin\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Greg Folin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/mannkind-corporation-nasdaqmnkd-receives-favorable-votes-from-advisory-panel-of-the-fda-for-its-diabetes-treatment-18579#article\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/mannkind-corporation-nasdaqmnkd-receives-favorable-votes-from-advisory-panel-of-the-fda-for-its-diabetes-treatment-18579\"},\"author\":{\"name\":\"Greg Folin\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/09a8586a8976289812879bbc81ac988e\"},\"headline\":\"Mannkind Corporation (NASDAQ:MNKD) Receives Favorable Votes From Advisory Panel Of The FDA For Its Diabetes Treatment\",\"datePublished\":\"2014-04-03T13:48:20+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/mannkind-corporation-nasdaqmnkd-receives-favorable-votes-from-advisory-panel-of-the-fda-for-its-diabetes-treatment-18579\"},\"wordCount\":343,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/mannkind-corporation-nasdaqmnkd-receives-favorable-votes-from-advisory-panel-of-the-fda-for-its-diabetes-treatment-18579#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/04\/MannKind-Corp..jpg\",\"keywords\":[\"MannKind Corporation (NASDAQ:MNKD)\",\"NASDAQ:MNKD\"],\"articleSection\":[\"Health\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/cablemanpro.com\/wallstreetpr\/mannkind-corporation-nasdaqmnkd-receives-favorable-votes-from-advisory-panel-of-the-fda-for-its-diabetes-treatment-18579#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/mannkind-corporation-nasdaqmnkd-receives-favorable-votes-from-advisory-panel-of-the-fda-for-its-diabetes-treatment-18579\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/mannkind-corporation-nasdaqmnkd-receives-favorable-votes-from-advisory-panel-of-the-fda-for-its-diabetes-treatment-18579\",\"name\":\"Mannkind Corporation (NASDAQ:MNKD) Receives Favorable Votes From Advisory Panel Of The FDA For Its Diabetes Treatment - Wall Street PR\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/mannkind-corporation-nasdaqmnkd-receives-favorable-votes-from-advisory-panel-of-the-fda-for-its-diabetes-treatment-18579#primaryimage\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/mannkind-corporation-nasdaqmnkd-receives-favorable-votes-from-advisory-panel-of-the-fda-for-its-diabetes-treatment-18579#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/04\/MannKind-Corp..jpg\",\"datePublished\":\"2014-04-03T13:48:20+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/mannkind-corporation-nasdaqmnkd-receives-favorable-votes-from-advisory-panel-of-the-fda-for-its-diabetes-treatment-18579#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/cablemanpro.com\/wallstreetpr\/mannkind-corporation-nasdaqmnkd-receives-favorable-votes-from-advisory-panel-of-the-fda-for-its-diabetes-treatment-18579\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/mannkind-corporation-nasdaqmnkd-receives-favorable-votes-from-advisory-panel-of-the-fda-for-its-diabetes-treatment-18579#primaryimage\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/04\/MannKind-Corp..jpg\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/04\/MannKind-Corp..jpg\",\"width\":441,\"height\":114},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/mannkind-corporation-nasdaqmnkd-receives-favorable-votes-from-advisory-panel-of-the-fda-for-its-diabetes-treatment-18579#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Mannkind Corporation (NASDAQ:MNKD) Receives Favorable Votes From Advisory Panel Of The FDA For Its Diabetes Treatment\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"name\":\"Wall Street PR\",\"description\":\"Latest News From WallStreet\",\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\",\"name\":\"Wall Street PR\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"width\":537,\"height\":70,\"caption\":\"Wall Street PR\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/WallStreetPR\/\",\"https:\/\/x.com\/WallstreetPRs\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/09a8586a8976289812879bbc81ac988e\",\"name\":\"Greg Folin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2020\/05\/4w1JQvu5_400x400-300x300.jpg\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2020\/05\/4w1JQvu5_400x400-300x300.jpg\",\"caption\":\"Greg Folin\"},\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/author\/greg-folin\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Mannkind Corporation (NASDAQ:MNKD) Receives Favorable Votes From Advisory Panel Of The FDA For Its Diabetes Treatment - Wall Street PR","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/cablemanpro.com\/wallstreetpr\/mannkind-corporation-nasdaqmnkd-receives-favorable-votes-from-advisory-panel-of-the-fda-for-its-diabetes-treatment-18579","og_locale":"en_US","og_type":"article","og_title":"Mannkind Corporation (NASDAQ:MNKD) Receives Favorable Votes From Advisory Panel Of The FDA For Its Diabetes Treatment - Wall Street PR","og_description":"Boston, MA 04\/03\/2014 (wallstreetpr) &#8211;\u00a0MannKind Corporation (NASDAQ:MNKD) moves a step ahead in getting its first product marketed as the drugmaker\u2019s inhaled diabetes treatment wins the [&hellip;]","og_url":"https:\/\/cablemanpro.com\/wallstreetpr\/mannkind-corporation-nasdaqmnkd-receives-favorable-votes-from-advisory-panel-of-the-fda-for-its-diabetes-treatment-18579","og_site_name":"Wall Street PR","article_publisher":"https:\/\/www.facebook.com\/WallStreetPR\/","article_published_time":"2014-04-03T13:48:20+00:00","og_image":[{"width":441,"height":114,"url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/04\/MannKind-Corp..jpg","type":"image\/jpeg"}],"author":"Greg Folin","twitter_misc":{"Written by":"Greg Folin","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/mannkind-corporation-nasdaqmnkd-receives-favorable-votes-from-advisory-panel-of-the-fda-for-its-diabetes-treatment-18579#article","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/mannkind-corporation-nasdaqmnkd-receives-favorable-votes-from-advisory-panel-of-the-fda-for-its-diabetes-treatment-18579"},"author":{"name":"Greg Folin","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/09a8586a8976289812879bbc81ac988e"},"headline":"Mannkind Corporation (NASDAQ:MNKD) Receives Favorable Votes From Advisory Panel Of The FDA For Its Diabetes Treatment","datePublished":"2014-04-03T13:48:20+00:00","mainEntityOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/mannkind-corporation-nasdaqmnkd-receives-favorable-votes-from-advisory-panel-of-the-fda-for-its-diabetes-treatment-18579"},"wordCount":343,"commentCount":0,"publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/mannkind-corporation-nasdaqmnkd-receives-favorable-votes-from-advisory-panel-of-the-fda-for-its-diabetes-treatment-18579#primaryimage"},"thumbnailUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/04\/MannKind-Corp..jpg","keywords":["MannKind Corporation (NASDAQ:MNKD)","NASDAQ:MNKD"],"articleSection":["Health"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/cablemanpro.com\/wallstreetpr\/mannkind-corporation-nasdaqmnkd-receives-favorable-votes-from-advisory-panel-of-the-fda-for-its-diabetes-treatment-18579#respond"]}]},{"@type":"WebPage","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/mannkind-corporation-nasdaqmnkd-receives-favorable-votes-from-advisory-panel-of-the-fda-for-its-diabetes-treatment-18579","url":"https:\/\/cablemanpro.com\/wallstreetpr\/mannkind-corporation-nasdaqmnkd-receives-favorable-votes-from-advisory-panel-of-the-fda-for-its-diabetes-treatment-18579","name":"Mannkind Corporation (NASDAQ:MNKD) Receives Favorable Votes From Advisory Panel Of The FDA For Its Diabetes Treatment - Wall Street PR","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/mannkind-corporation-nasdaqmnkd-receives-favorable-votes-from-advisory-panel-of-the-fda-for-its-diabetes-treatment-18579#primaryimage"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/mannkind-corporation-nasdaqmnkd-receives-favorable-votes-from-advisory-panel-of-the-fda-for-its-diabetes-treatment-18579#primaryimage"},"thumbnailUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/04\/MannKind-Corp..jpg","datePublished":"2014-04-03T13:48:20+00:00","breadcrumb":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/mannkind-corporation-nasdaqmnkd-receives-favorable-votes-from-advisory-panel-of-the-fda-for-its-diabetes-treatment-18579#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/cablemanpro.com\/wallstreetpr\/mannkind-corporation-nasdaqmnkd-receives-favorable-votes-from-advisory-panel-of-the-fda-for-its-diabetes-treatment-18579"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/mannkind-corporation-nasdaqmnkd-receives-favorable-votes-from-advisory-panel-of-the-fda-for-its-diabetes-treatment-18579#primaryimage","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/04\/MannKind-Corp..jpg","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/04\/MannKind-Corp..jpg","width":441,"height":114},{"@type":"BreadcrumbList","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/mannkind-corporation-nasdaqmnkd-receives-favorable-votes-from-advisory-panel-of-the-fda-for-its-diabetes-treatment-18579#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/cablemanpro.com\/wallstreetpr\/"},{"@type":"ListItem","position":2,"name":"Mannkind Corporation (NASDAQ:MNKD) Receives Favorable Votes From Advisory Panel Of The FDA For Its Diabetes Treatment"}]},{"@type":"WebSite","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","name":"Wall Street PR","description":"Latest News From WallStreet","publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization","name":"Wall Street PR","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","width":537,"height":70,"caption":"Wall Street PR"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/WallStreetPR\/","https:\/\/x.com\/WallstreetPRs"]},{"@type":"Person","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/09a8586a8976289812879bbc81ac988e","name":"Greg Folin","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2020\/05\/4w1JQvu5_400x400-300x300.jpg","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2020\/05\/4w1JQvu5_400x400-300x300.jpg","caption":"Greg Folin"},"url":"https:\/\/cablemanpro.com\/wallstreetpr\/author\/greg-folin"}]}},"_links":{"self":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/18579","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/users\/32"}],"replies":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/comments?post=18579"}],"version-history":[{"count":0,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/18579\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media\/18492"}],"wp:attachment":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media?parent=18579"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/categories?post=18579"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/tags?post=18579"},{"taxonomy":"stock_ticker","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/stock_ticker?post=18579"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}